Special Issue "Marine Polysaccharides"

Quicklinks

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 28 February 2015

Special Issue Editor

Guest Editor
Dr. Paola Laurienzo
Istituto di Chimica e Tecnologia dei Polimeri, C.N.R.-Via Campi Flegrei, 34-80078 Pozzuoli (Naples), Italy
Website: http://www.ictp.cnr.it/laurienzo.html
E-Mail: paola.laurienzo@ictp.cnr.it
Fax: +39 818 675 230

Special Issue Information

Dear Colleagues,

Biopolymers, as natural polysaccharides, are considered benign polymers for what concerns the environment. This is not a new invention, but at best a renaissance: the first type of polymers used by human kind were animal hides, cellulose, silk, wool. Among benefits of natural occurring biopolymers there are potential biocompatibility, renewable resources, low processing costs, tailoring of structure by genetic manipulation, and, as said, environmentally compatibility. Limits are, sometimes, premature degradation and high production costs due to the very high purity required for medical uses. Polysaccharides are not drugs by themselves, but their use in pharmaceutical field, for example as drug carriers or antimicrobial, anti-inflammatory or anticoagulant agents, is increasingly promising. Marine polysaccharides include chitin, chitosan, alginate, agar and carrageenans. Chitosan is a cationic carbohydrate biopolymer derived from chitin, the second most abundant polysaccharides present in nature after cellulose. The main sources of chitin are the shell wastes of shrimps, lobsters and crabs. For its characteristics, chitosan founds particular application as non viral vector in gene delivery. Films from chitosan are very tough and long lasting. Alginates derive from seaweed extraction (pheophyceae), and are mainly used in drug delivery and as hydrogels for immobilizing cells and enzymes, due to the mild conditions of cross-linking through bivalent cations (Ca2+). Agar (or agar-agar) and carrageenans are linear polysaccharides from red seaweeds. They are highly reactive chemically and are peculiar for thermoreversible gel formation. Exopolysaccharides (EPS), substantial components of the extracellular matrix of many cells of marine origin, also have to be mentioned for their potential interest in pharmaceuticals, and new EPS producing bacteria, particularly from extreme marine environments, are being isolated.
The possibility of chemical modification, blending and addition of biodegradable additives allows to tailor the final properties of polysaccharides and opens the doors to wider applications, particularly in pharmaceutical area. This issue is intended to explore any new potentiality of marine polysaccharides, as those above mentioned, deriving from chemical or chemical-physical modifications, and the scaling-up of their pharmaceutical applications.

Dr. Paola Laurienzo
Guest Editor

Keywords

  • chitosan
  • alginate
  • agar
  • carrageenans
  • exopolysaccharides
  • chemical modification
  • drug delivery
  • gene delivery

Published Papers (17 papers)

by , , , , , , ,  and
Mar. Drugs 2013, 11(11), 4464-4477; doi:10.3390/md11114464
Received: 11 September 2013; in revised form: 12 October 2013 / Accepted: 12 October 2013 / Published: 11 November 2013
Show/Hide Abstract | Cited by 1 | PDF Full-text (964 KB) | HTML Full-text | XML Full-text | Supplementary Files

by , , , ,  and
Mar. Drugs 2013, 11(3), 747-774; doi:10.3390/md11030747
Received: 17 December 2012; in revised form: 28 January 2013 / Accepted: 6 February 2013 / Published: 11 March 2013
Show/Hide Abstract | Cited by 6 | PDF Full-text (768 KB) | HTML Full-text | XML Full-text
abstract graphic

by , , , , , , ,  and
Mar. Drugs 2012, 10(11), 2560-2570; doi:10.3390/md10112560
Received: 20 August 2012; in revised form: 25 October 2012 / Accepted: 6 November 2012 / Published: 13 November 2012
Show/Hide Abstract | PDF Full-text (631 KB) | HTML Full-text | XML Full-text

by , , ,  and
Mar. Drugs 2012, 10(10), 2138-2152; doi:10.3390/md10102138
Received: 17 August 2012; in revised form: 10 September 2012 / Accepted: 13 September 2012 / Published: 25 September 2012
Show/Hide Abstract | Cited by 6 | PDF Full-text (1964 KB) | HTML Full-text | XML Full-text | Supplementary Files

by ,  and
Mar. Drugs 2011, 9(12), 2572-2604; doi:10.3390/md9122572
Received: 10 October 2011; in revised form: 18 November 2011 / Accepted: 22 November 2011 / Published: 8 December 2011
Show/Hide Abstract | Cited by 5 | PDF Full-text (852 KB) | HTML Full-text | XML Full-text

by , , , , , , , ,  and
Mar. Drugs 2011, 9(11), 2188-2200; doi:10.3390/md9112188
Received: 14 September 2011; in revised form: 17 October 2011 / Accepted: 24 October 2011 / Published: 2 November 2011
Show/Hide Abstract | Cited by 8 | PDF Full-text (499 KB) | HTML Full-text | XML Full-text
abstract graphic

by ,  and
Mar. Drugs 2011, 9(10), 1914-1954; doi:10.3390/md9101914
Received: 3 August 2011; in revised form: 7 September 2011 / Accepted: 13 September 2011 / Published: 14 October 2011
Show/Hide Abstract | Cited by 8 | PDF Full-text (1943 KB) | HTML Full-text | XML Full-text

by
Mar. Drugs 2011, 9(10), 1731-1760; doi:10.3390/md9101731
Received: 26 August 2011; in revised form: 22 September 2011 / Accepted: 26 September 2011 / Published: 30 September 2011
Show/Hide Abstract | Cited by 23 | PDF Full-text (266 KB) | HTML Full-text | XML Full-text

by , , , , , , , ,  and
Mar. Drugs 2011, 9(9), 1664-1681; doi:10.3390/md9091664
Received: 22 July 2011; in revised form: 2 September 2011 / Accepted: 5 September 2011 / Published: 23 September 2011
Show/Hide Abstract | Cited by 23 | PDF Full-text (6037 KB) | HTML Full-text | XML Full-text

by
Mar. Drugs 2011, 9(9), 1510-1533; doi:10.3390/md9091510
Received: 26 July 2011; in revised form: 28 August 2011 / Accepted: 31 August 2011 / Published: 9 September 2011
Show/Hide Abstract | Cited by 31 | PDF Full-text (644 KB) | HTML Full-text | XML Full-text

by , ,  and
Mar. Drugs 2011, 9(6), 1038-1055; doi:10.3390/md9061038
Received: 1 May 2011; in revised form: 25 May 2011 / Accepted: 7 June 2011 / Published: 14 June 2011
Show/Hide Abstract | Cited by 14 | PDF Full-text (558 KB) | HTML Full-text | XML Full-text

by , , , , , ,  and
Mar. Drugs 2010, 8(9), 2480-2492; doi:10.3390/md8092480
Received: 22 July 2010; in revised form: 30 August 2010 / Accepted: 3 September 2010 / Published: 6 September 2010
Show/Hide Abstract | Cited by 4 | PDF Full-text (1311 KB) | HTML Full-text | XML Full-text

by
Mar. Drugs 2010, 8(9), 2435-2465; doi:10.3390/md8092435
Received: 22 July 2010; in revised form: 19 August 2010 / Accepted: 20 August 2010 / Published: 2 September 2010
Show/Hide Abstract | Cited by 36 | PDF Full-text (481 KB) | HTML Full-text | XML Full-text
abstract graphic

by , , , , ,  and
Mar. Drugs 2010, 8(8), 2240-2251; doi:10.3390/md8082240
Received: 8 June 2010; in revised form: 16 July 2010 / Accepted: 28 July 2010 / Published: 30 July 2010
Show/Hide Abstract | Cited by 8 | PDF Full-text (188 KB) | HTML Full-text | XML Full-text

by , , , , ,  and
Mar. Drugs 2010, 8(7), 2038-2064; doi:10.3390/md8072038
Received: 13 May 2010; in revised form: 11 June 2010 / Accepted: 28 June 2010 / Published: 1 July 2010
Show/Hide Abstract | Cited by 33 | PDF Full-text (326 KB) | HTML Full-text | XML Full-text

by ,  and
Mar. Drugs 2010, 8(6), 1779-1802; doi:10.3390/md8061779
Received: 8 May 2010; in revised form: 25 May 2010 / Accepted: 2 June 2010 / Published: 3 June 2010
Show/Hide Abstract | Cited by 33 | PDF Full-text (350 KB) | HTML Full-text | XML Full-text
abstract graphic

by , , , , ,  and
Mar. Drugs 2010, 8(6), 1763-1768; doi:10.3390/md8061763
Received: 15 April 2010; in revised form: 14 May 2010 / Accepted: 26 May 2010 / Published: 28 May 2010
Show/Hide Abstract | Cited by 12 | PDF Full-text (133 KB) | HTML Full-text | XML Full-text

Last update: 7 May 2014

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert